Department of Neurology, St Vincent's Hospital, Sydney, NSW, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia; Department of Radiology, St Vincent's Hospital, Sydney, NSW, Australia.
Mult Scler Relat Disord. 2019 Oct;35:100-103. doi: 10.1016/j.msard.2019.07.016. Epub 2019 Jul 20.
Secondary autoimmune disorders (AID) are a recognised complication of alemtuzumab treatment for multiple sclerosis. We have previously reported two female multiple sclerosis patients treated with alemtuzumab who developed rare but severe secondary AID; acquired haemophilia A and autoimmune encephalitis with seizures. Both cases proved to be refractory to treatment with conventional immuno-therapy. However, treatment of the patients with anti-CD20 therapy resulted in sustained remission. This observation validates anti-CD20 therapy as a potential treatment option in patients with autoimmune complications of alemtuzumab that are postulated to arise as a result of B cell hyperpopulation.
继发自身免疫性疾病（AID）是阿仑单抗治疗多发性硬化症的已知并发症。我们之前曾报道过两名接受阿仑单抗治疗的多发性硬化症女性患者，她们出现了罕见但严重的继发 AID；获得性血友病 A 和伴有癫痫发作的自身免疫性脑炎。这两种情况均被证明对常规免疫治疗无反应。然而，用抗 CD20 治疗对患者进行治疗导致持续缓解。这一观察结果证实了抗 CD20 治疗作为阿仑单抗引起的自身免疫并发症患者的一种潜在治疗选择的有效性，这些并发症据推测是由于 B 细胞过度增殖引起的。
